Sidley Austin is advising GlycoMimetics, Inc. on the transaction, and Gibson, Dunn & Crutcher is advising Crescent Biopharma, Inc. GlycoMimetics, Inc. (NASDAQ: GLYC) announced it has...
GlycoMimetics’ Acquisition of Crescent Biopharma
Ocuphire Pharma’s Acquisition of Opus Genetics
Sidley Austin represented Ocuphire Pharma, Inc. in the transaction, and Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan represented Opus Genetics Inc. Wilson Sonsini Goodrich & Rosati...
HealthCare Royalty’s $250 Million Note Purchase Agreement With OPKO Health
Sidley Austin advised Healthcare Royalty on the deal. HealthCare Royalty, a leading royalty acquisition company, announced its US$250 million non-dilutive note purchase agreement with OPKO Health,...
Biolojic Design’s Collaboration with Merck KGaA, Darmstadt, Germany
Sidley Austin represented Biolojic Design, Ltd. in the deal. Biolojic Design, Ltd. (Biolojic), a biotechnology company, announced it has entered into a multi-target drug discovery collaboration...
Carlin Consumer Health’s Acquisition of Penetrex
Sidley Austin represented Carlin Consumer Health in the transaction, and Jones Day represented American Pacific Group. Carlin Consumer Health (“Carlin”) announced its acquisition of PENETREX® (“Penetrex”)...
BigHat Biosciences’ Collaboration with Janssen Biotech
Sidley Austin represented BigHat Biosciences in the transaction. BigHat Biosciences, a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform, announced its collaboration...
Pyxis Oncology’s $50 Million Shares Private Placement
Sidley Austin represented Pyxis Oncology, Inc. on the deal. Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company, announced that it agreed to sell 8,849,371 shares of...
Sagard Healthcare’s $200 Million Royalty Purchase Agreement with MannKind Corporation
Sidley Austin represented Sagard Healthcare in the transaction, and Cooley represented MannKind Corporation. Sagard Healthcare (Sagard) announced it entered into a royalty purchase agreement, under which...
Praxis Precision Medicines’ $264 Milion Collaboration and License Agreement with Tenacia Biotechnology
Sidley Austin represented Praxis Precision Medicines, Inc. in the transaction, and Ropes & Gray advised Tenacia. Praxis Precision Medicines, Inc. (NASDAQ: PRAX) announced it has entered...
Novo Nordisk’s Partnership with Evotec SE to Launch Translational Drug Discovery Accelerator
Sidley Austin LLP represented Novo Nordisk Inc. in the matter. Novo Nordisk (NYSE: NVO) announced its collaboration with Evotec SE (NASDAQ: EVO) to launch LAB eN² (pronounced Lab...
Carlin Consumer Health’s Acquisition of Infirst USA Holdings
Sidley Austin LLP served as legal advisor to Carlin and Wilson Sonsini Goodrich Rosati acted as legal advisor to Infirst. Stifel acted as exclusive financial advisor...
Pyxis Oncology’s Acquisition of Apexigen
Sidley Austin LLP advised Pyxis Oncology, Inc. on the transaction, while Wilson Sonsini advised Apexigen on the transaction. Pyxis Oncology, Inc., a clinical-stage company, and Apexigen,...